Bioceres Crop Solutions Corp

Bioceres Crop Solutions Corp(BIOX)股票分析

$0.255

+0.011 (+4.12%)收盘时

Loading chart…
最高
0.274
开盘
0.242
成交量加权均价
0.26
成交量
151.19K
市值
675.55M
最低
0.242
成交额
38.87K
企业价值/息税折旧摊销前利润(TTM)
0.00

Bioceres Crop Solutions Corp. is a provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. Its segments include Seed and integrated products, Crop protection and Crop nutrition. Seed and integrated products segment focuses on the development and commercialization of seed technologies and products, including provision of seed technologies integrated with crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics. Crop protection segment includes the development, production and marketing of adjuvants and a range of pest control molecules and biocontrol products. Crop nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers, including biofertilizers and micro-granulated fertilizers that optimize the productivity and yield of the crops.

AI 分析 of Bioceres Crop Solutions Corp (BIOX)

卖出

Given the current price of 0.27555 and a troubling RSI of 7.735, which indicates that the stock is heavily oversold, it may seem tempting to buy. However, the company has reported a staggering 79.59% decline year-to-date and a net income loss of -27500000 in the latest quarter, which raises significant red flags. The ongoing litigation risks and a gross margin that has dropped to 24.21% further complicate the investment case. Therefore, despite the oversold conditions, the fundamental weaknesses and risks suggest that this is not a good buy right now.

估值指标

Bioceres Crop Solutions Corp(BIOX)当前预期市盈率为 14.99,5 年平均预期市盈率为 21.54。

预期市盈率

合理
5 年均值 P/E
21.54
当前P/E
14.99
高估
33.42
低估
9.67

预期 EV/EBITDA

严重低估
5 年均值 EV/EBITDA
10.03
当前EV/EBITDA
0.00
高估
12.04
低估
8.02

预期市销率

严重低估
5 年均值 P/S
1.32
当前P/S
0.00
高估
1.83
低估
0.80

Alphio AI 对 BIOX 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%BIOX

$4.41

情景价格

基

基准

基准 · 50%BIOX

$4.26

情景价格

悲

悲观

悲观 · 25%BIOX

$3.79

情景价格

持有 BIOX 的大户

F

Fourth Sail Capital LP

+ 持有BIOX

-7.08%

3个月收益率

事件时间线

2026-09-14 (ET)

19:00:00

Bioceres Q4 Revenue at $55.9M, CEO Highlights Business Restructuring

2026-05-11 (ET)

17:10:00

Bioceres Reports Q3 Revenue of $39.4M

2026-03-16 (ET)

08:10:00

Bioceres CEO Discusses Financial Challenges and Restructuring Plans

2025-09-23 (ET)

07:05:26

Bioceres and Colorado Wheat Research Foundation Collaborate on HB4 Wheat Commercialization

资讯

BIOX 常见问题 —— 由 Alphio AI 解答

Bioceres Crop Solutions Corp. is a provider of crop productivity technologies designed to enable the transition of agriculture towards carbon neutrality. Its segments include Seed and integrated products, Crop protection and Crop nutrition. Seed and integrated products segment focuses on the development and commercialization of seed technologies and products, including provision of seed technologies integrated with crop protection and crop nutrition products designed to control weeds, insects or diseases, to increase their quality characteristics. Crop protection segment includes the development, production and marketing of adjuvants and a range of pest control molecules and biocontrol products. Crop nutrition segment focuses on the development, production and commercialization of inoculants that allow the biological fixation of nitrogen in the crops, and of fertilizers, including biofertilizers and micro-granulated fertilizers that optimize the productivity and yield of the crops. It operates in the Basic Materials sector.

Given the current price of 0.27555 and a troubling RSI of 7.735, which indicates that the stock is heavily oversold, it may seem tempting to buy. However, the company has reported a staggering 79.59% decline year-to-date and a net income loss of -27500000 in the latest quarter, which raises significant red flags. The ongoing litigation risks and a gross margin that has dropped to 24.21% further complicate the investment case. Therefore, despite the oversold conditions, the fundamental weaknesses and risks suggest that this is not a good buy right now.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易